Fusarium

Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole

Retrieved on: 
Montag, April 15, 2024

LONDON, April 15, 2024 (GLOBE NEWSWIRE) --  Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced topline results from the OPERA-S study: a Phase 2 safety and tolerability study in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against pulmonary aspergillosis. Opelconazole is an investigational inhaled triazole antifungal being developed to prevent and treat pulmonary aspergillosis. In this study, opelconazole was generally well tolerated with a low incidence of drug-related adverse events (AEs) and a low incidence of treatment-limiting respiratory AEs. Importantly, there were no dose reductions or discontinuations of opelconazole prophylaxis or of immunosuppressant medications due to opelconazole-related drug-drug interactions (DDIs). Despite the expected small numbers, there was evidence of prevention of pulmonary aspergillosis and of eradication in the lungs of both Aspergillus and Candida colonization with opelconazole monotherapy.

Key Points: 
  • In this study, opelconazole was generally well tolerated with a low incidence of drug-related adverse events (AEs) and a low incidence of treatment-limiting respiratory AEs.
  • Importantly, there were no dose reductions or discontinuations of opelconazole prophylaxis or of immunosuppressant medications due to opelconazole-related drug-drug interactions (DDIs).
  • Importantly, respiratory AEs related to opelconazole were rarely treatment-limiting, leading to discontinuation in two out of 65 opelconazole patients.
  • Three patients in the study died: one in the opelconazole group (1.5%) and two in the SOC group (6%).

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Mittwoch, März 27, 2024

BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

Key Points: 
  • Aspergillus fumigatus is also included in the FDA qualified designation list of pathogens that pose a serious and life-threatening risk.
  • Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc.
  • Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Retrieved on: 
Freitag, März 22, 2024

The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.

Key Points: 
  • The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.
  • She was transitioned to oral MAT2203 for two weeks, which led to clinical resolution of her fungal infection.
  • She began to show clinical improvement following two weeks of oral MAT2203 treatment and her skin wounds completely healed following six months of MAT2203 treatment.
  • “MAT2203 continues to demonstrate its potential to effectively treat invasive fungal infections and help patients achieve complete clinical resolution.

2024 Predictive Ag Report Warns Midwest Growers of Emerging Threats

Retrieved on: 
Dienstag, März 5, 2024

The 2024 Predictive Ag Report can be downloaded from Pattern Ag, the leading soil metagenomics company.

Key Points: 
  • The 2024 Predictive Ag Report can be downloaded from Pattern Ag, the leading soil metagenomics company.
  • EMERYVILLE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Armed with the 2024 Predictive Ag Report, released today by Pattern Ag, corn and soybean farmers can unlock the full potential of their crops, boosting both yield and profitability.
  • Packed into the 2024 Predictive Ag Report, Pattern Ag unveils an Almanac pinpointing regions facing the highest risk of pest and pathogen outbreaks.
  • “This year’s Predictive Ag report builds upon last year’s report, uncovering other hidden yield robbers found in Midwest corn and soybean fields,” said Mike Tweedy, Vice President of Sales for Pattern Ag.

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Retrieved on: 
Montag, Februar 26, 2024

BEDMINSTER, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today provided an update from its ongoing Compassionate/Expanded Use Access Program (the “Program”) with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.

Key Points: 
  • Treatment with MAT2203 was well tolerated and led to favorable clinical and radiological response and we did not observe any renal toxicity.
  • 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned.
  • 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease.
  • “We continue to be excited about the ongoing, consistent positive clinical impact of MAT2203, seen in these extremely ill patients,” said Theresa Matkovits, PhD, Chief Development Officer at Matinas .

CGIAR/Alliance of Bioversity Int'l & CIAT and Boost Biomes announce a project to evaluate biological treatment for critical diseases of bananas

Retrieved on: 
Mittwoch, Juli 26, 2023

BERKELEY, Calif. and ROME, July 26, 2023 /PRNewswire/ -- CGIAR research center Alliance of Bioversity International and CIAT ("Alliance/CGIAR"), and Boost Biomes, Inc. ("Boost") announced today the initiation of a project to evaluate Boost's biological products to address Fusarium wilt in bananas.

Key Points: 
  • BERKELEY, Calif. and ROME, July 26, 2023 /PRNewswire/ -- CGIAR research center Alliance of Bioversity International and CIAT ("Alliance/CGIAR"), and Boost Biomes, Inc. ("Boost") announced today the initiation of a project to evaluate Boost's biological products to address Fusarium wilt in bananas.
  • Alliance solutions address the global crises of malnutrition, climate change, biodiversity loss, and environmental degradation.
  • Their joint program will address diseases in bananas for which there is currently no effective treatment, and where biological products are preferred, starting with Fusarium wilt Tropical Race 4.
  • We look forward to working with the Alliance/CGIAR on this first product, and advanced products generated via our platform technology."

What do the different colours of mould mean in my house?

Retrieved on: 
Montag, Juni 26, 2023

The air and surfaces around you are home to multitudes of bacteria, fungi, viruses, mites, algae and protozoa.

Key Points: 
  • The air and surfaces around you are home to multitudes of bacteria, fungi, viruses, mites, algae and protozoa.
  • A lot of this fungal growth is what we call mould.
  • But what do the myriad colours that appear on our stuff tell us about the world we try not to think about?

Black

    • The concept of toxic black mould is one many people have become aware of due to flood impacts.
    • Stachybotrys is the one known as toxic black mould.
    • When the grout in your shower turns black though, that’s a different fungus called Aureobasidium.

Blue

    • That blue orange I mentioned before, you can thank Penicillium for that.
    • The organism that gives us blue cheese and the antibiotic penicillin is also responsible for producing a dense growth of mould that almost looks like smoke when disturbed, spreading millions of spores onto the rest of your fruit bowl.

Yellow and orange

    • In fact, some need exposure to light – and ultraviolet (UV) light in particular – to complete their life cycle.
    • They produce a spectrum of staining that can often turn damp items yellow, brown or orange.

Green

    • We’re all fairly familiar with the green spots that turn up on mouldy bread, cake and other food items.
    • The green tuft is often from a group of fungi called Aspergillus.
    • In the green gang is also a fungus called Trichoderma, which is Latin for “hairy skin”.

Pink, purple and red

    • Neurospora, also known as the red bread mould, is one of the most studied fungi in scientific literature.
    • It’s another common, non-hazardous one that has been used as a model organism to observe fungal genetics, evolution and growth.
    • Fusarium is less common indoors, being an important crop pathogen, but will sometimes turn spoiled rice purple.

White

    • One of these was hyaline and non-hyaline, essentially referring to transparent and coloured, respectively.
    • This fungus is a parasite of some moths and cicadas and is visible as brilliant white, tree-shaped growths on their unfortunate hosts.

Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use

Retrieved on: 
Montag, Juni 12, 2023

The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.

Key Points: 
  • The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.
  • Applied BioCode’s Fungal Panel is intended for research use only and may be used in infectious disease research or pharmaceutical development.
  • “Applied BioCode is thrilled to announce our first release of an RUO panel under our new product strategy.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.

New 10- & 20-Gallon Grow Bags Perfect for Outdoor Cannabis Cultivation from bio365

Retrieved on: 
Donnerstag, März 2, 2023

Cultivators can grow bigger, denser plants in 20-gallon bags of bio365 media than 40-gallon containers of any other media.

Key Points: 
  • Cultivators can grow bigger, denser plants in 20-gallon bags of bio365 media than 40-gallon containers of any other media.
  • Since 2015, bio365 has offered its line of innovative grow media, made with multiple patented ingredients designed to deliver better results for indoor and outdoor cultivators.
  • "Outdoor cannabis growers have been asking for larger bio365 grow bags for years," says bio365 Chief Operating Officer Sean Meshorer.
  • As a result, cannabis cultivators who grow in bio365 media use less soil, reduce labor and amendment costs, and get better results.

Certis Biologicals Introduces BioFungicide SoilGard® to Provide Disease Protection for Greenhouse and Agriculture Specialty Crops

Retrieved on: 
Mittwoch, Februar 22, 2023

The product has a wide-variety of label uses, including in greenhouses and nurseries as well as on agricultural food crops and ornamentals.

Key Points: 
  • The product has a wide-variety of label uses, including in greenhouses and nurseries as well as on agricultural food crops and ornamentals.
  • SoilGard is OMRI-Listed® and approved for use in organic and conventional agriculture.
  • “SoilGard provides growers with another sustainable, environmentally-friendly tool to protect a wide variety of crops against the diseases that threaten them,” says Tim Riley, National Sales Director.
  • To learn more about Certis Biologicals, their portfolio of proven solutions, and their commitment to sustainability, visit www.CertisBio.com or follow the company through social media on Facebook , Twitter , LinkedIn and Instagram .